One study showed that KRAS gene mutations existed in approximately 25% of the tumor tissues of TKI-insensitive patients, and another randomized controlled study showed that KRAS gene mutations were one of the factors influencing the efficacy of TKIs [46,47,48,49]. The gene discussed is KRAS; the disease is neoplasm.